Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04094961 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ixazomib + Pomalidomide + Dexamethasone In MM

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv10
  2. Primary completion date: Oct 1, 2024 to Jun 1, 2025v9
  3. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 61 to confirmed 52 · Primary completion date changed from estimate of Dec 20, 2024 to Oct 1, 2024 · Completion date: Dec 20, 2024 to Jan 1, 2027 · 1 morev8 Show 4 more changesShow less
    • Enrollment target: estimated 61 to confirmed 52
    • Primary completion date changed from estimate of Dec 20, 2024 to Oct 1, 2024
    • Completion date: Dec 20, 2024 to Jan 1, 2027
    • Site details revised
  4. Lead sponsor: Paul Richardson, MD to Omar Nadeem, MD Primary and study completion dates: Mar 20, 2024 to Dec 20, 2024 · Site contact updatedv7 Show 2 more changesShow less
    • Primary and study completion dates: Mar 20, 2024 to Dec 20, 2024
    • Site contact updated
  5. Lead sponsor: Paul G. Richardson, MD to Paul Richardson, MDv6
Show 4 earlier versionsHide 4 earlier versions
  1. Primary and study completion dates: Mar 20, 2022 to Mar 20, 2024v5
  2. 2 versions Re-verified since Feb 17, 2021, no change to tracked fieldsv3-v4
  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 2019 to Sep 18, 2019 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Sep 2019 to Sep 18, 2019
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.
Trial Details
NCT Number NCT04094961
Lead Sponsor Omar Nadeem, MD
Collaborators: Takeda
Conditions Multiple Myeloma, Multiple Myeloma in Relapse
Enrollment 52 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov